Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: “We are pleased to report another strong quarter, resulting in a very good performance during the first nine months. Nutrition and Materials once again delivered organic growth rates well above their respective markets, with particularly good volume growth.
These results demonstrate significantly improved operational and financial performance, well ahead of plan, with all businesses delivering on their ambitious growth initiatives, and we are firmly on track with our cost-reduction and efficiency improvement programs. Furthermore, we successfully divested our share in Patheon ahead of schedule.
DSM confirms its full year 2017 outlook, despite slightly less favorable currency developments. In addition, with all of these developments ahead of plan we are bringing forward our regular strategic review process for the period beyond 2018 and anticipate communicating the results before mid-year 2018, as announced at our September Investor Event.”
Strong performance in Q3, contributing to very good first nine months
Sales up 9% to €6,456m, with 8% organic growth
Adjusted EBITDA up 15% to €1,086m, driven by both Nutrition and Materials
ROCE up 170 bps to 12.3%
Adjusted Net profit up 29% to €504m
Total Net profit of €1,603m, including gain on Patheon disposal of €1,250m
Outlook 2017 unchanged